TSHA — Taysha Gene Therapies, Inc.

Taysha Gene Therapies, Inc. (TSHA) Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Net Loss: $109 million for FY 2025, or $0.34 per share, compared to a net loss of $89.3 million, or $0.36 per share in FY 2024.
• R&D Expenses: Increased to $86.4 million from $66 million in the previous year, primarily due to higher compensation and clinical trial costs.
• G&A Expenses: Rose to $33.9 million from $29 million, attributed to increased compensation, legal fees, and debt issuance costs.
• Cash Position: $319.8 million in cash and equivalents as of December 31, 2025, with additional $50 million raised in Q4 through an equity offering, expected to fund operations into 2028.

2. Strategic Updates and Business Highlights

• Clinical Progress: Significant advancements in the TSHA-102 program, including compelling Phase 1/2 data for Rett syndrome, FDA Breakthrough Therapy designation, and initiation of the pivotal REVEAL trial.
• FDA Alignment: Received FDA clearance for the ASPIRE trial, which will evaluate the safety and preliminary efficacy of TSHA-102 in younger patients.
• Market Opportunity: Estimated 15,000 to 20,000 patients in the U.S., EU, and UK with Rett syndrome, highlighting a strong unmet need and potential demand for TSHA-102.
• Commercial Readiness: Strengthened commercial leadership with the appointment of Brad Martin as SVP of Market Access and Value, focusing on building out internal capabilities for potential commercialization.

3. Forward Guidance and Outlook

• Pivotal Trial Timeline: Dosing for the REVEAL pivotal trial is on track to complete in 2026, with interim data expected in Q2 2026.
• BLA Submission: Plans for a Biologics License Application (BLA) submission are contingent on positive interim data; potential for rolling submission based on clinical data.
• Market Research: Indications of strong demand for TSHA-102, particularly for its intrathecal administration route, which is favored by both clinicians and caregivers.

4. Bad News, Challenges, or Points of Concern

• Increased Losses: The net loss widened compared to the previous year, raising concerns about financial sustainability as the company approaches commercialization.
• Regulatory Risks: While the FDA has shown support, the pathway to approval remains contingent on the success of ongoing trials and data integrity.
• Competitive Landscape: Concerns about potential competitive pressures from other gene therapies, particularly following negative feedback received by competitors, which may impact market dynamics.

5. Notable Q&A Insights

• Intrathecal Administration Preference: There is strong community support for the intrathecal route due to its familiarity and perceived safety compared to more invasive methods.
• Market Access Strategy: The company plans to engage payers early to build relationships and educate them on the patient population and clinical data.
• Data Pooling Strategy: The ability to pool data from different trials may enhance the robustness of the BLA submission, allowing for comprehensive safety and efficacy analyses.
• Patient Enrollment: Enrollment in pivotal studies is progressing well, with multiple patients already dosed, and the company is confident in meeting its timelines.

Overall, Taysha Gene Therapies is positioned for a transformative year ahead, with promising clinical data and a clear regulatory strategy, despite facing financial losses and competitive pressures.